TNFSF10 and lung carcinoma: The combined treatment of volasertib and TRAIL enhanced the sub-G1 population, PARP cleavage, and downregulation of c-FLIP expression in A498 (renal carcinoma cells) and A549 cells (lung carcinoma) (Figure 7A,B).